On 1 April 2026, Japan's Pharmaceuticals and Medical Devices Agency did something no other major medicines regulator had done before it: from that date, every new drug, device and diagnostic application had to arrive in a single, metadata-driven electronic format — eCTD v4.0 — with no grace period and no fallback to the older standard. It is the kind of change that never makes a headline outside regulatory-affairs circles, and the kind that quietly reshapes how an entire market moves. Japan, long caricatured as the most exacting and most patient of the big agencies, had decided to lead the world into the next generation of digital submissions.

That single date is a useful way to read the mood of the whole region. Across Asia-Pacific, the machinery of drug approval is being rewired for speed. South Korea runs a fast-track designation that aims to clear innovative medicines in around 90 days. India has pushed its industry onto a single digital portal and is piloting electronic submissions that bring it closer to global norms. Reliance pathways — where one authority leans on the assessment of a more established one rather than repeating the whole review — are spreading through Southeast Asia and Oceania. The direction of travel is unmistakable: harmonise the paperwork, digitalise the pipes, and shorten the wait.

For patients, that is mostly good news. For the people who have to watch what happens after a medicine reaches the market, it raises an uncomfortable question that the region has not yet fully answered. Every system that has aggressively accelerated approvals has, sooner or later, had to reckon with the medicines it let through that should not have stayed. The relevant experience is not hypothetical, and it is not Asian — it is American, and it is instructive precisely because the United States built its expedited pathways first and has spent the last five years cleaning up after them.

The question for Asia, then, is not whether to go faster. That decision has effectively been made. The question is whether the surveillance, the confirmatory-evidence discipline and the willingness to reverse a bad approval are being built at the same pace as the acceleration itself. If they are not, the region is not buying speed. It is buying risk on credit.

The push: harmonise the paperwork, digitalise the pipes

Start with what is actually changing, because the digitalisation story and the acceleration story are easy to conflate and are not the same thing.

The digitalisation push is, at heart, about removing friction. The electronic Common Technical Document — eCTD — is the standardised structure in which a modern drug dossier is assembled and transmitted. Its newest version, v4.0, was developed under the International Council for Harmonisation's M8 working group and is designed to let sponsors reuse documents across applications, track changes more cleanly, and exchange information with reviewers in two directions rather than one. The United States began accepting v4.0 marketing applications in late 2024; the European Medicines Agency opened an optional route at the end of 2025. Japan went furthest, fastest, moving from a technical pilot in 2021 through a voluntary window to a hard mandate in April 2026 — becoming the first major authority to make the format compulsory.

India is earlier in the same journey but moving in the same direction. Its industry now routes regulatory filings through the government's SUGAM portal, and the Central Drugs Standard Control Organisation has run an eCTD pilot allowing voluntary electronic submissions for selected application types since 2023. Surveys suggest the large majority of India's bigger pharmaceutical companies have implemented, or are implementing, eCTD tooling in anticipation of a future mandate. The friction of paper — physical dossiers, manual version control, broken cross-references — is being engineered out.

Layered on top of digitalisation is convergence: the slow alignment of what regulators ask for, not just how it is delivered. India has been bringing its technical requirements into line with ICH guidelines. Through the Asia-Pacific Economic Cooperation forum's Regulatory Harmonisation Steering Committee, regional regulators run shared training and build common reference points. And reliance — the willingness to accept or lean on a stringent authority's prior review — is becoming a deliberate resource-allocation strategy. Australia's Therapeutic Goods Administration formalises it through its comparable-overseas-regulator pathways; smaller agencies across ASEAN increasingly use the World Health Organization's collaborative registration procedure to avoid duplicating work they do not have the capacity to do well.

None of this, on its own, is acceleration in the dangerous sense. A cleaner dossier and a shared rulebook make review faster and better at the same time. The risk does not live in the plumbing. It lives in the expedited evidence standards that sit alongside the plumbing — the priority reviews, conditional approvals and fast-track designations that let a medicine onto the market before the full clinical picture is in. That is where speed and safety actually trade against each other, and South Korea is the clearest regional example of a system that has leaned in.

The case for speed: the patients who cannot wait

The argument for going faster is not abstract, and it is worth stating in its strongest form before picking it apart.

South Korea launched its Global Innovative Products on Fast Track programme — GIFT — in 2022, modelled in spirit on the US breakthrough-therapy designation. It designates treatments for severe, intractable and rare diseases, and innovative new drugs, for priority handling, with a rapid-review division running the non-clinical, clinical and quality assessments in parallel rather than in sequence. The target is approval in roughly 90 days against a standard review of around 120 — a meaningful compression for a patient with a disease that does not pause for paperwork. The GIFT programme sits on top of a fast-track system that, in its first two years, cleared more than twenty drugs, including orphan, oncology and COVID products, and it is paired with a conditional-approval mechanism that allows earlier authorisation on promising-but-limited data in exchange for post-marketing study commitments.

The logic is threefold. First, unmet need: for rare and intractable conditions, patient numbers are small, alternatives are few, and the cost of waiting is measured in lives, not quarters. Second, access equity: Korea's own researchers have documented that, despite the country's efficient review machinery, its patients have historically waited one to two years longer than American or European patients to get many new cancer drugs — a lag driven mostly by when sponsors choose to file, not by how long the agency takes once they do. Faster, more attractive pathways are partly an effort to pull those submissions forward so Korean patients stop being an afterthought in global launch sequencing. Third, competitiveness: a region that wants to host clinical trials, attract first-in-Asia launches and grow a domestic biotech base cannot be the slowest door in the building.

That third point is the one regulators say least about in public and feel most acutely in private. Speed is a sovereign asset. When Singapore, Korea, Japan and increasingly India compete to be where a global sponsor launches first in Asia, review timelines become an instrument of industrial policy. The danger in that framing is obvious: the moment "fastest" becomes a competitive boast, the pressure runs in exactly one direction, and the institutional incentive to pump the brakes weakens precisely when it matters most.

The case for caution: what the fast lane has actually produced

Here is where the region should be reading other people's history closely, because the United States has already run the experiment Asia is now scaling.

The US accelerated-approval pathway lets a drug onto the market on the strength of a surrogate endpoint — an intermediate marker, such as tumour shrinkage or a lab value, judged "reasonably likely" to predict real clinical benefit — on the condition that the sponsor later runs a confirmatory trial to prove that benefit is real. It is an elegant bargain in theory. In practice, the confirmatory half of the bargain has been the weak link, and the numbers are sobering.

Since the pathway's inception, roughly 13 percent of all accelerated-approval drug applications have been withdrawn — and, tellingly, about half of those withdrawals came after January 2021, as scrutiny intensified. A 2022 federal Inspector General review found that 35 of the 104 accelerated-approval drugs that had not yet finished their confirmatory trials had already fallen behind their original completion dates; four were running between five and twelve years late. The same review estimated that public payers spent more than US$18 billion over four years on drugs whose confirmatory evidence was overdue. Patients were taking — and taxpayers were funding — medicines whose central promise remained unproven, sometimes for the better part of a decade.

Two cases became cautionary shorthand. Makena, a treatment to prevent preterm birth, received accelerated approval in 2011 on a surrogate endpoint. Its confirmatory trial failed to show benefit; the agency's drug-evaluation centre proposed withdrawal in 2020; the sponsor demanded a hearing; and the drug was not finally pulled until April 2023 — twelve years on the market, and roughly a decade after the confirmatory data should have settled the question. The withdrawal required a three-day hearing, a fifteen-person advisory panel and a docket of hundreds of documents to remove a medicine that, by the regulator's own conclusion, lacked substantial evidence of effectiveness. As the FDA commissioner put it at the time, the touchstone of approval is a favourable benefit-risk balance, and without that favourable assessment a drug should not keep its approved status. The system's problem was not the original judgement call. It was how astonishingly hard it proved to undo.

The second case, Aduhelm, an Alzheimer's therapy approved in 2021 on a contested surrogate marker, was divisive enough that three members of the agency's own advisory committee resigned over the decision. Congressional and Inspector General investigations followed; coverage restrictions gutted its commercial prospects; the sponsor discontinued it in 2024. Around the same controversy, US lawmakers passed reforms — the Food and Drug Omnibus Reform Act — that gave the agency clearer authority to require confirmatory trials be underway before approval and to withdraw failed drugs through a faster process. The reform is the tell: the world's most experienced expedited-approval system concluded, after thirty years, that its single biggest design flaw was the gap between letting a drug in quickly and getting it out when the evidence did not arrive.

That is the lesson Asia should internalise. The headline risk of acceleration is not that regulators approve a few drugs that later disappoint. Some of that is the unavoidable price of treating desperate patients on incomplete data, and a system that never makes that bet is too conservative. The real risk is asymmetry: approval is fast, frictionless and celebrated, while withdrawal is slow, adversarial, expensive and politically radioactive. A pathway that accelerates entry without equally accelerating exit does not balance speed against safety. It systematically tilts toward keeping things on the market.

Where the line should sit — and why surveillance must scale with speed

If acceleration is here to stay, the question becomes design: what has to be true for "faster" to remain safe? Three things, on the evidence.

First, confirmatory evidence has to be a condition, not a courtesy. The most useful finding from the US experience is that accelerated approvals whose confirmatory trials were already up and running at the time of approval were far more likely to convert to full approval or to be cleanly withdrawn — rather than drifting for years in limbo. The fix is structural and unglamorous: require the confirmatory trial to be designed, agreed and ideally enrolling before the conditional approval is granted, with hard, published deadlines and pre-specified consequences for missing them. Korea's conditional-approval and GIFT frameworks already attach post-marketing obligations; the open question, which regional regulators rarely disclose in detail, is how rigorously those obligations are tracked and what actually happens when a sponsor slips. A commitment with no enforced deadline is a wish.

Second, post-market surveillance has to scale in lockstep with approval speed — and in Asia it largely has not yet. The logic is simple: if you move risk-bearing decisions from before approval to after it, your safety net has to be strong enough to catch what you let through. That means well-resourced pharmacovigilance, mandatory risk-management plans, active (not merely passive) signal detection, and the data infrastructure to run post-authorisation safety studies. Reviews of post-authorisation study practice across China, Japan and South Korea have flagged exactly the gaps that matter: inconsistent regulatory expectations, uneven access to real-world data, and a need to harmonise how safety questions are studied after launch. Korea operates a functioning pharmacovigilance system and can require risk-management plans; the harder problem, region-wide, is that surveillance capacity is unevenly distributed and rarely funded to expand at the same rate as the acceleration programmes that make it necessary. Every fast-track designation is, in effect, a promissory note written against the surveillance system. Asia is writing the notes faster than it is funding the system that has to honour them.

Third, reliance has to flow both ways. The region's growing use of reliance — accepting a stringent authority's review to move faster — is sensible resource allocation, but it carries a subtle hazard: a medicine can be approved across several Asian markets on the strength of one foreign decision, which means a single flawed approval can propagate widely before anyone catches it. Reliance on the approval therefore has to be matched by reliance on the withdrawal — the same shared infrastructure that lets a good drug spread quickly must let a bad one be pulled quickly, and the safety signal detected in one market must travel to the others as fast as the original authorisation did. That reverse channel is the least-developed piece of the regional architecture, and it is precisely the piece the Makena saga proves you cannot do without.

There is a tempting middle position that says the two risks cancel out — go fast, and fix mistakes later. The US record is the rebuttal. Fixing mistakes later turned out to mean a twelve-year fight to withdraw a single drug that did not work. The asymmetry is not a footnote; it is the whole problem. Building the exit ramp is harder, less rewarding and less visible than building the on-ramp, which is exactly why it gets underbuilt — and exactly why a region accelerating as deliberately as Asia-Pacific now is should be building it first.

How to read "faster"

For the executives, investors and clinicians who consume regulatory news as a stream of approval announcements, the practical takeaway is a way of reading the word faster without mistaking it for looser — or for safe.

A faster approval is a statement about process efficiency, and very often a genuine good: a parallel review, a cleaner digital dossier, a sensible reliance decision that spares an under-resourced agency from re-reviewing what a stringent regulator already settled. None of that lowers the evidence bar, and the region's digitalisation drive — eCTD v4.0, SUGAM, the convergence work running through ICH and APEC — belongs squarely in this category. Be glad of it.

A faster approval can also be a statement about evidence timing — a decision to act on a surrogate endpoint now and confirm the real benefit later. That is a legitimate bet for serious diseases with no alternatives, but it is a bet, and the only honest way to read it is to ask the three questions the US learned the hard way: Is the confirmatory trial already running, with a real deadline? Is the post-market surveillance system strong enough to catch what slips through? And if the evidence never arrives, can this medicine actually be removed — quickly, and across every market that relied on the original decision?

Where the answer to all three is yes, "faster" is exactly what it claims to be: better access without a hidden cost. Where the answer is no, the speed is real but the safety is borrowed, and someone — a patient, a payer, a future regulator running a three-day withdrawal hearing — eventually pays it back with interest. Asia's accelerated-approval gamble is not reckless. But it is a gamble, and the house edge sits entirely in the surveillance and exit machinery that the region is, for now, building more slowly than the speed it is so visibly proud of.

(arcilla.fran@biopharmaapac.com)

Disclaimer: This article is an editorial policy analysis prepared for informational purposes only. It does not constitute medical, legal, regulatory or investment advice, and should not be relied upon as a substitute for guidance from a qualified professional or from the relevant national authority. Drug names, approval statuses, regulatory timelines and figures cited are believed to be accurate as of the date of publication and are included for illustration; regulatory positions and product approvals change over time and should be verified against primary sources before any decision is taken. References to specific medicines, companies or agencies are illustrative and do not imply endorsement, criticism, or any statement about the current marketing status of any product. The views expressed are those of the author and do not necessarily reflect those of the publication, its editors, or any organisation, regulator or company named herein.